Stephen T. Durant

3.3k citations

33 papers · 2.0k indexed · 1 hit paper · h-index 20

Co-authors: Holly Robertson John D. Hayes Steven Vitale T.M. Penning Albena T. Dinkova‐Kostova Jac A. Nickoloff Nicholas B. La Thangue Martin Jansson
Topics: DNA Repair Mechanisms (19 papers)Glioma Diagnosis and Treatment (7 papers)Carcinogens and Genotoxicity Assessment (4 papers)
Cited by: Molecular Biology Oncology Cancer Research
Journals: Proceedings of the National Academy of Sciences Nucleic Acids ResearchSHILAP Revista de lepidopterología
Partner nations: United Kingdom United States Singapore

In The Last Decade

Stephen T. Durant

33 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease

2015 672 citations Holly Robertson, Stephen T. Durant et al. Free Radical Biology and Medicine profile →

Peers

Countries citing papers authored by Stephen T. Durant

Since Specialization

Citations

This map shows the geographic impact of Stephen T. Durant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen T. Durant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen T. Durant more than expected).

Fields of papers citing papers by Stephen T. Durant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen T. Durant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen T. Durant. The network helps show where Stephen T. Durant may publish in the future.

Co-authorship network of co-authors of Stephen T. Durant

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen T. Durant. A scholar is included among the top collaborators of Stephen T. Durant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen T. Durant. Stephen T. Durant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis 2023 ·Clinical Cancer Research ·Ben Yi Tew,(unknown),(unknown),Kyle Hurth,Thomas R. Simon,(unknown),Stephen T. Durant,Petra Hamerlik,Bodour Salhia	15
2	ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer 2022 ·BMC Cancer ·S. Lindsey Davis,Sarah J. Hartman,Stacey M. Bagby,(unknown),Betelehem W. Yacob,Tonia E. Tse,(unknown),Jennifer R. Diamond,Christopher H. Lieu,Alexis D. Leal,Elaine Cadogan,Gareth Hughes,Stephen T. Durant,Wells A. Messersmith,Todd M. Pitts	21
3	ALT neuroblastoma chemoresistance due to telomere dysfunction–induced ATM activation is reversible with ATM inhibitor AZD0156 2021 ·Science Translational Medicine ·(unknown),Ahsan Farooqi,Thinh H. Nguyen,(unknown),Ashly Hindle,(unknown),Monish Ram Makena,(unknown),Joanne Wilson,Aaron Smith,Venkatesh Pilla Reddy,Elaine Cadogan,Stephen T. Durant,C. Patrick Reynolds	40
4	Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models 2020 ·British Journal of Cancer ·(unknown),Yann Wallez,Timothy Isaac Johnson,Sandra Bernaldo de Quirós Fernández,Stephen T. Durant,Elaine Cadogan,Alan Lau,Frances M. Richards,Duncan I. Jodrell	37
5	Abstract 4720: Ataxia telangiectasia mutated (ATM) kinase inhibitor AZD0156 in combination with 5-fluorouracil and irinotecan in preclinical models of colorectal cancer 2019 ·Cancer Research ·S. Lindsey Davis,(unknown),Stacey M. Bagby,Sarah J. Hartman,Betelehem W. Yacob,Tonia E. Tse,(unknown),Jennifer R. Diamond,Christopher H. Lieu,Alexis D. Leal,Elaine Cadogan,Gareth Hughes,Stephen T. Durant,Wells A. Messersmith,Todd M. Pitts	1
6	Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors 2018 ·ACS Medicinal Chemistry Letters ·Bernard Barlaam,Elaine Cadogan,Andrew D. Campbell,Nicola Colclough,Allan Dishington,Stephen T. Durant,Kristin Goldberg,Lorraine Hassall,Gareth Hughes,Philip A. MacFaul,Thomas M. McGuire,Martin Pass,Anil S. Patel,Stuart E. Pearson,Jens Petersen,Kurt G. Pike,Graeme R. Robb,Natalie Stratton,(unknown),(unknown)	19
7	Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes 2017 ·PLoS ONE ·Thomas A. Ward,Peter J. McHugh,Stephen T. Durant	31
8	Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active site 2016 ·Nature Chemical Biology ·(unknown),Mark J. Thompson,L. David Finger,(unknown),J.E. Debreczeni,Thomas A. Ward,Claire McWhirter,(unknown),Daniel Martinez Molina,W. Mark Abbott,Clifford D. Jones,J. Willem M. Nissink,Stephen T. Durant,Jane A. Grasby	56
9	Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative diseasebreakdown → 2015 ·Free Radical Biology and Medicine ·(unknown),Holly Robertson,Stephen T. Durant,Steven Vitale,T.M. Penning,Albena T. Dinkova‐Kostova,John D. Hayes	672
10	Development of a High-Throughput Fluorescence Polarization DNA Cleavage Assay for the Identification of FEN1 Inhibitors 2013 ·SLAS DISCOVERY ·Claire McWhirter,Michael Tonge,Helen Plant,(unknown),J. Willem M. Nissink,Stephen T. Durant	21
11	Structures of the Human Poly (ADP-Ribose) Glycohydrolase Catalytic Domain Confirm Catalytic Mechanism and Explain Inhibition by ADP-HPD Derivatives 2012 ·PLoS ONE ·Julie A. Tucker,(unknown),C. Brassington,Stephen T. Durant,(unknown),Geoffrey A. Holdgate,M. McAlister,J. Willem M. Nissink,(unknown),Martin Watson	48
12	Telomerase-Independent Paths to Immortality in Predictable Cancer Subtypes 2012 ·Journal of Cancer ·Stephen T. Durant	35
13	Metnase promotes restart and repair of stalled and collapsed replication forks 2010 ·Nucleic Acids Research ·Leyma P. De Haro,Justin Wray,Elizabeth A. Williamson,Stephen T. Durant,(unknown),(unknown),Neil Osheroff,Suk‐Hee Lee,Robert Hromas,Jac A. Nickoloff	49
14	p53 methylation—the Arg-ument is clear 2009 ·Cell Cycle ·Stephen T. Durant,(unknown),Nicholas B. La Thangue	22
15	DNA-PKcs and ATM co-regulate DNA double-strand break repair 2009 ·DNA repair ·Meena Shrivastav,Cheryl A. Miller,Leyma P. De Haro,Stephen T. Durant,Benjamin P.C. Chen,David J. Chen,Jac A. Nickoloff	108
16	Arginine methylation regulates the p53 response 2008 ·Nature Cell Biology ·Martin Jansson,Stephen T. Durant,(unknown),(unknown),Mariola J. Edelmann,Benedikt M. Kessler,Nicholas B. La Thangue	367
17	Good Timing in the Cell Cycle for Precise DNA Repair by BRCA1 2005 ·Cell Cycle ·Stephen T. Durant,Jac A. Nickoloff	51
18	Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX 2003 ·Oncogene ·(unknown),(unknown),Helen M.R. Robinson,Carol McCormick,Dorothy H. Crouch,Stephen T. Durant,Elizabeth Matheson,Andrew G. Hall,David A. Gillespie,Robert Brown	30
19	Vanillins--a novel family of DNA-PK inhibitors 2003 ·Nucleic Acids Research ·Stephen T. Durant	150
20	Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes 1999 ·Current Biology ·Stephen T. Durant,(unknown),(unknown),(unknown),Carol McCormick,Gillian L. Hirst,Rhona H. Borts,Robert Brown	83

About Stephen T. Durant

Stephen T. Durant is a scholar working on Genetics, Cancer Research and Aging, having authored 33 papers that have together received 2.0k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (19 papers), Glioma Diagnosis and Treatment (7 papers) and Carcinogens and Genotoxicity Assessment (4 papers). The work is most often cited by research in Molecular Biology (1.6k citations), Oncology (410 citations) and Cancer Research (215 citations). Stephen T. Durant has collaborated with scholars based in United Kingdom, United States and Singapore. Frequent co-authors include Holly Robertson, John D. Hayes, Steven Vitale, T.M. Penning, Albena T. Dinkova‐Kostova, Jac A. Nickoloff, Nicholas B. La Thangue, Martin Jansson, Benedikt M. Kessler and Mariola J. Edelmann. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact